ELVN
Enliven TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
ELVN vs peer average
72/100
ELVN vs. peer average (B vs. C)
Grade spread
B 3 · C 3 · D 3 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ABUS is the first available peer comparator.
Less direct scientifically, but a comparable sub-$1B biotech valuation comp that helps frame how clinical uncertainty and capital runway can dominate sentiment.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
ELVN
Enliven Therapeutics
ABUS
Arbutus Biopharma
Grade
B
B
Momentum
73
54
Value
41
41
Sentiment
58
77
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Constructive
Grade position vs ABUS
ELVN / ABUS
Grade Position
Above peers
ELVN vs. peer average (B vs. C)
72/100
Momentum
73
ELVNValue
41
ELVNSentiment
58
ABUSRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs ELVN
ABUS is the first peer returned for this comparison set.